The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HBRM | +9,900% | -96.3% | -48.23% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +426% |
Herborium Group, Inc. engages in the research, development, licensing, and trade of botanical therapeutic products. It offers acne treatment, energy drink, sexual enhancers, medication for erectile dysfunctions, and capsules for diabetes, refractory tumors, rheumatoid arthritis, and liver. The company was founded by Agnes Paulina Olszewski and James Patrick Gilligan on January 8, 1996 and is headquartered in Fort Lee, NJ.
No news articles found for Herborium Group.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $59.90K | -77.8% |
| Gross Profit | $40.90K | -71.0% |
| Gross Margin | 68.28% | 16.1% |
| Market Cap | $963.00K | 0.0% |
| Market Cap / Employee | $160.50K | 0.0% |
| Employees | 6 | 0.0% |
| Net Income | -$8.90K | -152.3% |
| EBITDA | -$8.90K | -152.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.00K | -31.7% |
| Accounts Receivable | $9.75K | 50.0% |
| Inventory | 0 | -58.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $401.59K | 0.0% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -217.98% | -211.6% |
| Return On Invested Capital | -2.32% | -3.9% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.00K | 0.0% |
| Operating Free Cash Flow | $0.00K | 0.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.26 | -0.26 | -0.26 | -0.26 | - |
| Price to Sales | 1.00 | 1.01 | 1.04 | 1.08 | 9.83% |
| Price to Tangible Book Value | -0.25 | -0.25 | -0.25 | -0.25 | -0.04% |
| Price to Free Cash Flow TTM | 11.40 | 11.60 | 11.60 | - | |
| Enterprise Value to EBITDA | 126.68 | -6.66 | 164.36 | -167.48 | -114.26% |
| Free Cash Flow Yield | 8.8% | 8.6% | 8.6% | - | |
| Total Debt | $1.07M | $1.07M | $1.07M | $401.59K | -62.44% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
